ALW-II-41-27

ALW-II-41-27 is a **small molecule inhibitor** that selectively targets **EPH family receptor tyrosine kinases**, primarily **EPHA2**. It exhibits nanomolar potency with an IC50 of approximately 11 nM for EPHA2. ALW-II-41-27’s mechanism involves the inhibition of EPHA2-mediated signaling, affecting downstream pathways such as PI3K/AKT/mTOR, RAS/RAF/MAPK, FAK, SRC, ABL, and RHO/RAC/CDC42. Preclinically, it has demonstrated anti-tumor effects, reducing tumor growth and increasing apoptosis in non–small cell lung cancer (NSCLC) models. In vitro and in vivo studies indicate anti-inflammatory activity, particularly by suppressing proinflammatory cytokine release in models of *Pneumocystis* pneumonia and reducing atherosclerosis-related inflammation. The drug has also shown efficacy in suppressing cell survival, proliferation, migration, and invasion in various cancers, such as lung, cervical, breast, and nasopharyngeal cancers, through inhibition of EPHA2-dependent signaling (including via the RhoA/ROCK pathway and Shp2/Erk-1/2). ALW-II-41-27 is used in preclinical research and is not approved for clinical use.